# Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

> **NCT02228460** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 11 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** GZ/SAR402671

## Key facts

- **NCT ID:** NCT02228460
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228460, "Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT02228460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*